A specific mistletoe preparation (Iscador-Qu®) in Colorectal Cancer (CRC) patients: More than just supportive care?

Journal of Cancer Science and Therapy

Volumn 4, Issue 9, 2012, Pages 264-270

  Zaenker, K S ^a   Matthes, H ^b   Bock, P R ^c   Hanisch, J ^c  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b Oncology Clinic   (Germany)

^c IFAG Basel AG   (Switzerland)

Author keywords

Chemo radiotherapy; CRC patients; Iscador Qu; Metastasis free interval; Supportive care; Therapy induced adverse effects; Viscum

Indexed keywords

ISCADOR QU; UNCLASSIFIED DRUG; VISCUM ALBUM EXTRACT;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS FREE SURVIVAL; OAK; OBSERVATIONAL STUDY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISCUM ALBUM;

EID: 84867533210     PISSN: None     EISSN: 19485956     Source Type: Journal    
DOI: 10.4172/1948-5956.1000153     Document Type: Article

References (27)

1. Krakowski I (2006) Supportive care for people affected by cancer: concept and management. Rev Pract 56: 1989-1996.
2. Balducci L (2009) Supportive care in elderly cancer patients. Curr Opin Oncol 21: 310-317.
3. Ernst E (2009) Complementary and alternative medicine (CAM) and cancer: the kind face of complementary medicine. Int J Surg 7: 499-500.
4. Gaertner J, Wolf J, Hallek M, Glossmann JP, Voltz R (2011) Standardizing integration of palliative care into comprehensive cancer therapy-a disease specific approach. Support Care Cancer 19: 1037-1043.
5. Storey DJ, Fallon MT, Smyth JF (2011) The interface between medical oncology and supportive and palliative cancer care. Semin Oncol 38: 337-342.
6. Peterson DE, Bensadoun RJ, Lalla RV, McGuire DB (2011) Supportive care treatment guidelines: value, limitations, and opportunities. Semin Oncol 38: 367-373.
7. Peppercorn JM, Smith TJ, Helft PR, Debono DJ, Berry SR, et al. (2011) American society of clinical oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol 29: 755-760.
8. Scialdone L (2012) Overview of supportive care in patients receiving chemotherapy: antiemetics, pain management, anemia, and neutropenia. J Pharm Pract 25: 209-221.
9. Estfan B (2011) Essential drugs in supportive care. Semin Oncol 38: 413-423.
10. Friedel WE, Matthes H, Bock PR, Zänker KS (2009) Systematic evaluation of the clinical effects of supportive mistletoe treatment within chemo- and/or radiotherapy protocols and long-term mistletoe application in nonmetastatic colorectal carcinoma: multicenter, controlled, observational cohort study. J Soc Integr Oncol 7: 137-145.
11. Feinstein A (1984) The role of observational studies in the evaluation of therapy. Stat Med 3: 341-345.
12. Horwitz RI, Viscoli CM, Clemens JD, Sadock RT (1990) Developing improved observational methods for evaluating therapeutic effectiveness. Am J Med 89: 630-638.
13. Benson K, Hartz AJ (2000) A comparison of observational studies and randomized, controlled trials. N Engl J Med 342: 1878-1886.
14. Garcia JM, Friend J, Allen S (2012) Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer.
15. Whelan TJ, Mohide EA, Willan AR, Arnold A, Tew M, et al. (1997) The supportive care needs of newly diagnosed cancer patients attending a regional cancer center. Cancer 80: 1518-1524.
16. Matthes H, Friedel WE, Bock PR, Zänker KS (2010) Molecular mistletoe therapy: friend or foe in established anti-tumor protocols? A multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer. Curr Mol Med 10: 430-439.
17. Eggenschwiler J, von Balthazar L, Stritt B, Pruntsch D, Ramos M, et al. (2007) Mistletoe lectin is not the only cytotoxic component in fermented preparations of Viscum album from white fir (Abies pectinata). BMC Complement Altern Med 7: 14.
18. Bantel H, Engels IH, Voelter W, Schulze-Osthoff K, Wesselborg S (1999) Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis. Cancer Res 59: 2083-2090.
19. Elluru S, Duong van Huyen JP, Wootla B Delignat S, Prost F, Negi VS, et al. (2007) Tumor regression of Viscum album preparations exploration of immunomodulatory mechanisms. Medicina (Buenos Aires) 67: 85-89.
20. Hegde P, Maddur MS, Friboulet A, Bayry J, Kaveri SV (2011) Viscum album exerts anti-inflammatory effect by selectively inhibiting cytokine-induced expression of cyclooxygenase-2. PLoS One 6: e26312.
21. Wagschal I, Eggenschwiler J, von Balthazar L, Patrignani A, Rehrauer H, et al. (2007). Gene expression signatures of pathway alterations in tumor cells caused by plant extracts. Medicine (Buenos Aires) 67: 97-106.
22. Hugo F, Schwitalla S, Niggemann B, Zänker KS, Dittmar T (2007) Viscum album extract Iscador®-P and Iscador®-M counteract the growth factor induced effects in human follicular B-NHL cells and breast cancer cells. Medicine (Buenos Aires) 67: 90-96.
23. Urech K, Schaller G, Jäggy C (2006) Viscotoxins, mistletoe lectins and their isoforms in mistletoe (Viscum album L) extracts Iscador. Arzneimittelforschung 56: 428-434.
24. Bandyopadhyay R, Chatterjee U, Mondal SK, Nag D, Sinha SK (2011) A study on expression pattern of cyclooxygenase-2 in carcinoma of cervix. Indian J Pathol Microbiol 54: 695-699.
25. Zhang L, Wu YD, Li P, Tu J, Niu YL, et al. (2011) Effects of cyclooxygenase-2 on human esophageal squamous cell carcinoma. World J Gastroenterol 17: 4572-4580.
26. Zaenker KS, Mihich E, Liu E (2011) Personalized Cancer Medicine 2011: Towards individualized cancer treatments. Transl Oncol 4: 198-201.
27. Margalit DN, Mamon HJ, Ancukiewicz M, Kobayashi W, Ryan DP, et al. (2011) Tolerability of combined modality therapy for rectal cancer in elderly patients aged 75 years and older. Int J Radiat Oncol Biol Phys 81: e735-e741.